Perspective Therapeutics, Inc. (CATX)
(Delayed Data from AMEX)
$1.75 USD
-0.05 (-2.78%)
Updated May 10, 2024 04:00 PM ET
After-Market: $1.75 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Income Statements
Fiscal Year end for Perspective Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 1 | 0 | 11 | 10 | 10 |
Cost Of Goods | 0 | 0 | 6 | 5 | 5 |
Gross Profit | 1 | 0 | 5 | 5 | 5 |
Selling & Adminstrative & Depr. & Amort Expenses | 42 | 0 | 12 | 9 | 9 |
Income After Depreciation & Amortization | -41 | 0 | -7 | -3 | -3 |
Non-Operating Income | -8 | 0 | 0 | 0 | 0 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -49 | 0 | -7 | -3 | -3 |
Income Taxes | -3 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -47 | 0 | -7 | -3 | -3 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -47 | 0 | -7 | -3 | -3 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -40 | 0 | -7 | -3 | -3 |
Depreciation & Amortization (Cash Flow) | 1 | 0 | 0 | 0 | 0 |
Income After Depreciation & Amortization | -41 | 0 | -7 | -3 | -3 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 267.64 | 141.99 | 103.84 | 67.60 | 67.04 |
Diluted EPS Before Non-Recurring Items | -0.14 | -0.05 | -0.03 | -0.05 | -0.08 |
Diluted Net EPS (GAAP) | -0.17 | -0.05 | -0.05 | -0.03 | -0.05 |
Fiscal Year end for Perspective Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | -4.90 | 2.19 | 2.09 | 2.06 |
Cost Of Goods | NA | -4.86 | 1.45 | 1.84 | 1.58 |
Gross Profit | NA | -4.90 | 0.74 | 0.25 | 0.49 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 7.77 | 11.27 | 11.62 | 11.72 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -12.67 | -10.53 | -11.37 | -11.23 |
Non-Operating Income | NA | -8.99 | 0.20 | 0.30 | 0.37 |
Interest Expense | NA | 0.02 | 0.01 | 0.03 | 0.02 |
Pretax Income | NA | -16.83 | -10.36 | -11.11 | -10.87 |
Income Taxes | NA | 7.85 | 0.00 | 0.00 | -10.50 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -24.68 | -10.36 | -11.11 | -0.37 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -24.68 | -10.36 | -11.11 | -0.37 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | NA | 280.56 | 279.99 | 228.59 |
Diluted EPS Before Non-Recurring Items | NA | NA | -0.04 | -0.04 | 0.00 |
Diluted Net EPS (GAAP) | NA | -0.09 | -0.04 | -0.04 | 0.00 |